BioSpace News Archive

Emmes, a global, full-service Clinical Research Organization dedicated to supporting the advancement of public health and biopharmaceutical innovation, announced that Kristin Judge has joined as its chief growth officer, a newly created executive leadership position.

HeartBeam, Inc. (NASDAQ: BEAT) today announced it has received a notice of allowance from The United States Patent and Trademark Office for a key patent relating to the initial AI capability in the form of an expert system for its HeartBeam AIMIGoTM System.

Microbot Medical Inc. announced that it has successfully achieved another major milestone representing the next step toward the regulatory and commercial paths for the LIBERTY® Robotic Surgical System, the first single-use endovascular robotic system.

Hememics Biotechnologies, Inc., developer of first-in-class, handheld, multiplexed biosensor platform that can test antibodies, antigens and molecular targets simultaneously, announced the closing of a $2 million Seed 2 financing round.

Sirona Biochem Corp. is pleased to announce it has contracted Atheln Inc., a leading US consulting firm, to bolster and facilitate Sirona’s business activities.

BriaCell Therapeutics Corp. is pleased to announce that it has entered into an arrangement agreement dated May 24, 2023 with BriaPro Therapeutics Corp., a wholly-owned subsidiary of the Company pursuant to which certain pre-clinical pipeline assets of the Company, including Bria-TILsRx™ and protein kinase C delta inhibitors for multiple indications including cancer, will be spun-out to SpinCo by way of a court approved statutory plan of arrangement under the Business Corporations Act .

AffaMed Therapeutics (“AffaMed”) announced today that its partner Allgenesis Biotherapeutics Inc., a clinical-stage specialty pharmaceutical company focused on developing novel ophthalmic drugs, reported exciting preliminary data from the two initial cohorts of the on-going AG-77305 FIH Phase 2a clinical trial for the treatment of Diabetic Macular Edema (DME) in the US.

Genedata today announced that Debiopharm, a Swiss-based, global biopharmaceutical company is adopting Genedata Profiler® as its single point of access to translational research data to accelerate its R&D activities and bring life-saving drugs faster to underserved patients.

During the conference on 23 May, French MedTech Biosency unveiled its latest clinical results demonstrating the ability of its BVS3 technology to predict acute COPD (chronic obstructive pulmonary disease) exacerbations on average 3 days prior to hospitalisation in 86% of cases, with only 9% false positives.

Synapse Medicine, the leader in medication success, and CompuGroup Medical, the leader in software for providers, have announced a partnership to accelerate innovation in prescribing and allow physicians to benefit from time-saving technological advances in clinical decision support.